Table 2.
Individual patient data
| Patient | Age | Gender | Age at onset | Clinical MRI | Antiepileptic medications | Digit span (normalized z-score) | List learning (normalized z-score) |
|---|---|---|---|---|---|---|---|
| 1 | 24 | F | 15 | HS | CARB, LEV, PREGAB | 10 | 0.44 |
| 2 | 18 | F | 9 | HS | LAM, CLOB, LEV | 6 | −0.5 |
| 3 | 40 | F | 30 | FCD | CARB, CLOB | 9 | −1.42 |
| 4 | 23 | F | 12 | HS | PHEN, LEV, CLOB, LAM | 10 | 0.13 |
| 5 | 42 | M | 36 | HS | LAM, LEV | 14 | 0.39 |
| 6 | 19 | F | 5 | NV | GAB, CLOB, CARB | 5 | N/A |
| 7 | 38 | M | 19 | NV | OXCARB, LACOS, CLOB, ACET | 7 | 0.53 |
| 8 | 23 | F | 2 | HS | LEV, OXCARB, ZON | 5 | −1.23 |
| 9 | 35 | F | 10 | HS | CARB, TOP | 6 | −0.72 |
| 10 | 24 | F | 17 | NV | LEV, CARB, CLOB | N/A | N/A |
| 11 | 32 | M | 22 | FCD | CARB, LEV, CLOB | 13 | −1.83 |
| 12 | 29 | F | 7 | NV | LAC, CLOB, LEV, TOP | 6 | −1.33 |
| 13 | 30 | M | 18 | NV | LAM, CARB | 6 | −0.81 |
| 14 | 35 | F | 18 | HS | LAM, LEV | 8 | −1.42 |
| 15 | 31 | M | 26 | NV | LEV, VAL | 16 | 0.23 |
| 16 | 49 | M | 7 | HS | LAM, GAB | 8 | −2.09 |
| 17 | 37 | M | 5 | HS | LEV, CARB, CLOB | 14 | −0.86 |
| 18 | 29 | F | 21 | HS | TOP, LAM, CLOB | 9 | −1.85 |
Note: CARB, carbamazepine; LEV, levetiracetam; PREGAB, pregabalin; LAM, lamotrigine; CLOB, clobazam; PHEN, phenytoin; GAB, gabapentin; OXCARB, oxcarbazepine; LAC, lacosamide; ACET, acetazolamide; ZON, zonisamide; TOP, topiramate; VAL, sodium valproate.